Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

It Ain't Over Till the Fat Lady Sings: The POPSTAR Trial.

Ost P.

Eur Urol. 2018 Oct;74(4):463-464. doi: 10.1016/j.eururo.2018.06.031. Epub 2018 Jul 6. No abstract available.

PMID:
30227925
2.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
3.

Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium.

Fonteyne V, Rammant E, Ost P, Lievens Y, De Troyer B, Rottey S, De Meerleer G, De Maeseneer D, De Ridder D, Decaestecker K.

Clin Genitourin Cancer. 2018 Aug 11. pii: S1558-7673(18)30241-6. doi: 10.1016/j.clgc.2018.07.026. [Epub ahead of print]

PMID:
30190222
4.

Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers.

Fonteyne V, Ost P.

Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30598-0. doi: 10.1016/j.eururo.2018.08.013. [Epub ahead of print] No abstract available.

PMID:
30174197
5.

Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?

Helsmoortel H, Everaert C, Lumen N, Ost P, Vandesompele J.

Noncoding RNA Res. 2018 May 23;3(2):64-74. doi: 10.1016/j.ncrna.2018.05.001. eCollection 2018 Jun. Review.

6.

Effects of radiation on the metastatic process.

Sundahl N, Duprez F, Ost P, De Neve W, Mareel M.

Mol Med. 2018 Apr 24;24(1):16. doi: 10.1186/s10020-018-0015-8. Review.

7.

Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer.

Buelens S, De Bleser E, Dhondt B, Verla W, Decaestecker K, Ost P, Fonteyne V, De Man K, Standaert C, Rottey S, Lumen N.

World J Urol. 2018 Aug 22. doi: 10.1007/s00345-018-2449-6. [Epub ahead of print]

PMID:
30132067
8.

Imaging modalities in synchronous oligometastatic prostate cancer.

Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer A, Ost P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere PJL, Tsaur I; EAU-YAU Prostate Cancer Working Party.

World J Urol. 2018 Aug 1. doi: 10.1007/s00345-018-2416-2. [Epub ahead of print]

PMID:
30069582
9.

Stereotactic Body Radiotherapy for Primary Prostate Cancer.

Kothari G, Loblaw A, Tree AC, van As NJ, Moghanaki D, Lo SS, Ost P, Siva S.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789633. doi: 10.1177/1533033818789633.

10.

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma.

Brochez L, Meireson A, Chevolet I, Sundahl N, Ost P, Kruse V.

Nat Commun. 2018 Jul 26;9(1):2921. doi: 10.1038/s41467-018-05047-1. No abstract available.

11.

Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?

Ploussard G, Borgmann H, Briganti A, de Visschere P, Fütterer JJ, Gandaglia G, Heidegger I, Kretschmer A, Mathieu R, Ost P, Sooriakumaran P, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R; EAU-YAU Prostate Cancer Working Group.

World J Urol. 2018 Jul 2. doi: 10.1007/s00345-018-2399-z. [Epub ahead of print]

PMID:
29967944
12.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

13.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11.

PMID:
29892016
14.

Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile.

Meireson A, Chevolet I, Hulstaert E, Ferdinande L, Ost P, Geboes K, De Man M, Van de Putte D, Verset L, Kruse V, Demetter P, Brochez L.

Oncotarget. 2018 May 18;9(38):25216-25224. doi: 10.18632/oncotarget.25393. eCollection 2018 May 18.

15.

Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, Lambert B, Delrue L, De Meerleer G.

J Clin Oncol. 2018 Aug 1;36(22):2351-2352. doi: 10.1200/JCO.2018.78.2144. Epub 2018 Jun 1. No abstract available.

PMID:
29856691
16.

How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.

Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).

BJU Int. 2018 May 17. doi: 10.1111/bju.14391. [Epub ahead of print]

PMID:
29772103
17.

Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row

Fodor A, Lancia A, Ceci F, Picchio M, Hoyer M, Jereczek-Fossa BA, Ost P, Castellucci P, Incerti E, Di Muzio N, Ingrosso G.

World J Urol. 2018 May 11. doi: 10.1007/s00345-018-2322-7. [Epub ahead of print]

PMID:
29752513
18.

Pelvic lymph node dissection in prostate cancer staging: evaluation of morbidity and oncological outcomes.

Van Huele A, Poelaert F, Fonteyne V, Decaestecker K, Ost P, Lumen N.

Acta Chir Belg. 2018 May 8:1-7. doi: 10.1080/00015458.2018.1470294. [Epub ahead of print]

PMID:
29734878
19.

Live to SABR Another Day?

Tran PT, Feng F, Ost P.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1097. doi: 10.1016/j.ijrobp.2018.01.104. No abstract available.

PMID:
29722652
20.

Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology.

van den Bergh RCN, Ost P, Surcel C, Valerio M, Fütterer JJ, Gandaglia G, Sooriakumaran P, Tilki D, Tsaur I, Ploussard G; European Association of Urology Working Party on Prostate Cancer (EAU-YAUWP).

World J Urol. 2018 Sep;36(9):1489-1494. doi: 10.1007/s00345-018-2278-7. Epub 2018 Apr 2.

PMID:
29610962
21.

More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis.

Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA.

Eur Urol. 2018 Aug;74(2):134-137. doi: 10.1016/j.eururo.2018.02.024. Epub 2018 Mar 12.

PMID:
29544737
22.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
23.

Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.

Sundahl N, De Wolf K, Kruse V, Meireson A, Reynders D, Goetghebeur E, Van Gele M, Speeckaert R, Hennart B, Brochez L, Ost P.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):906-915. doi: 10.1016/j.ijrobp.2017.11.029. Epub 2017 Nov 24.

PMID:
29485070
24.

4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial.

Fonteyne V, Sarrazyn C, Swimberghe M, De Meerleer G, Rammant E, Vanderstraeten B, Vanpachtenbeke F, Lumen N, Decaestecker K, Colman R, Villeirs G, Ost P.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):866-870. doi: 10.1016/j.ijrobp.2017.12.016. Epub 2017 Dec 19.

PMID:
29485064
25.

Is 68Ga-Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?

Chandrasekar T, Ost P, Tilki D.

Eur Urol. 2018 May;73(5):662-663. doi: 10.1016/j.eururo.2018.01.029. Epub 2018 Feb 19. No abstract available.

PMID:
29472144
26.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
27.

Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction.

Buelens S, Claeys T, Dhondt B, Poelaert F, Vynck M, Yigit N, Thas O, Ost P, Vandesompele J, Lumen N, Kumps C.

Clin Genitourin Cancer. 2018 Jun;16(3):197-205.e5. doi: 10.1016/j.clgc.2017.12.008. Epub 2017 Dec 29.

PMID:
29366632
28.

Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.

Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Visschere P, Ost P, Verbeke S, Villeirs G, De Man K, Rottey S, Decaestecker K, Lumen N.

Urol Oncol. 2018 Apr;36(4):158.e13-158.e20. doi: 10.1016/j.urolonc.2017.12.009. Epub 2018 Jan 12.

PMID:
29336978
29.

Pembrolizumab for the treatment of bladder cancer.

Sundahl N, Rottey S, De Maeseneer D, Ost P.

Expert Rev Anticancer Ther. 2018 Feb;18(2):107-114. doi: 10.1080/14737140.2018.1421461. Epub 2017 Dec 29.

PMID:
29284318
30.

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G.

J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14.

PMID:
29240541
31.

A systematic review of exercise and psychosocial rehabilitation interventions to improve health-related outcomes in patients with bladder cancer undergoing radical cystectomy.

Rammant E, Decaestecker K, Bultijnck R, Sundahl N, Ost P, Pauwels NS, Deforche B, Pieters R, Fonteyne V.

Clin Rehabil. 2018 May;32(5):594-606. doi: 10.1177/0269215517746472. Epub 2017 Dec 12.

PMID:
29231044
32.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.

PMID:
29229176
33.

Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer.

Bultijnck R, Van de Caveye I, Rammant E, Everaert S, Lumen N, Decaestecker K, Fonteyne V, Deforche B, Ost P.

BJU Int. 2018 Apr;121(4):610-618. doi: 10.1111/bju.14086. Epub 2018 Jan 10.

PMID:
29194928
34.

Availability of prostate cancer exercise rehabilitation resources and practice patterns in Belgium: Results of a cross-sectional study.

Bultijnck R, Van Ruymbeke B, Everaert S, Bagué H, Rammant E, Rimbaut S, Fonteyne V, Lumen N, Decaestecker K, Ost P.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12788. Epub 2017 Nov 2.

PMID:
29094773
35.

AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?

Tsaur I, Borgmann H, Surcel CI, Ost P, Ploussard G.

World J Urol. 2018 Jan;36(1):149-151. doi: 10.1007/s00345-017-2107-4. Epub 2017 Oct 30. No abstract available.

PMID:
29086020
36.

Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients.

Huysse W, Lecouvet F, Castellucci P, Ost P, Lambrecht V, Artigas C, Denis ML, Man K, Delrue L, Jans L, Bruycker A, Vos F, Meerleer G, Decaestecker K, Fonteyne V, Lambert B.

Diagnostics (Basel). 2017 Oct 17;7(4). pii: E56. doi: 10.3390/diagnostics7040056.

37.

Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39. doi: 10.1016/j.prro.2017.07.011. Epub 2017 Jul 20. Review.

38.

What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

Phillips R, Ost P, Tran PT.

Future Oncol. 2017 Oct;13(24):2121-2124. doi: 10.2217/fon-2017-0337. Epub 2017 Oct 11. No abstract available.

39.

Editorial Comment.

Poelaert F, Ost P, Lumen N.

Urology. 2017 Nov;109:151-152. doi: 10.1016/j.urology.2017.06.055. Epub 2017 Sep 21. No abstract available.

PMID:
28943047
40.

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.

De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L, Goetghebeur E, De Meerleer G, Lumen N, Fonteyne V, De Maeseneer D, Ost P.

Radiat Oncol. 2017 Sep 22;12(1):157. doi: 10.1186/s13014-017-0893-x.

41.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.

De Bleser E, Tran PT, Ost P.

Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441. Review.

PMID:
28816714
42.

Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.

van den Bergh R, Gandaglia G, Tilki D, Borgmann H, Ost P, Surcel C, Valerio M, Sooriakumaran P, Salomon L, Briganti A, Graefen M, van der Poel H, de la Taille A, Montorsi F, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).

Eur Urol Focus. 2017 Aug 8. pii: S2405-4569(17)30188-8. doi: 10.1016/j.euf.2017.07.003. [Epub ahead of print]

PMID:
28801241
43.

Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.

Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, Ingrosso G.

Eur Urol Focus. 2017 Dec;3(6):538-544. doi: 10.1016/j.euf.2017.07.006. Epub 2017 Aug 8. Review.

PMID:
28801240
44.

Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A.

Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]

PMID:
28779974
45.

Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey.

Bultijnck R, Surcel C, Ploussard G, Briganti A, De Visschere P, Fütterer J, Ghadjar P, Giannarini G, Isbarn H, Massard C, Sooriakumaran P, Valerio M, van den Bergh R, Ost P.

Eur Urol Focus. 2016 Dec;2(5):514-521. doi: 10.1016/j.euf.2016.02.009. Epub 2016 Mar 5.

PMID:
28723517
46.

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.

Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P, Reynders D, Van Gele M, Brochez L, Ost P.

J Transl Med. 2017 Jun 29;15(1):150. doi: 10.1186/s12967-017-1251-3.

47.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

48.

Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.

De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, Villeirs G, De Vos F, De Man K, Decaestecker K, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, Duthoy W, Ost P.

BJU Int. 2017 Dec;120(6):815-821. doi: 10.1111/bju.13938. Epub 2017 Jul 16.

PMID:
28646594
49.

Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3.

Tree AC, Siva S, Ost P.

Eur Urol. 2017 Sep;72(3):e66-e67. doi: 10.1016/j.eururo.2017.06.011. Epub 2017 Jun 20. No abstract available.

PMID:
28642019
50.

Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol.

Rammant E, Bultijnck R, Sundahl N, Ost P, Pauwels NS, Deforche B, Pieters R, Decaestecker K, Fonteyne V.

BMJ Open. 2017 Jun 6;7(5):e016054. doi: 10.1136/bmjopen-2017-016054. Review.

Supplemental Content

Support Center